key: cord-0813785-d31dms58
authors: Ong, Sean Wei Xiang; Fong, Siew-Wai; Young, Barnaby Edward; Chan, Yi-Hao; Lee, Bernett; Amrun, Siti Naqiah; Chee, Rhonda Sin-Ling; Yeo, Nicholas Kim-Wah; Tambyah, Paul; Pada, Surinder; Tan, Seow Yen; Ding, Ying; Renia, Laurent; Leo, Yee-Sin; Ng, Lisa F P; Lye, David Chien
title: Persistent symptoms and association with inflammatory cytokine signatures in recovered COVID-19 patients
date: 2021-04-02
journal: Open Forum Infect Dis
DOI: 10.1093/ofid/ofab156
sha: dc29696add7162464aa7e17d88ec83d1b2d2bd5f
doc_id: 813785
cord_uid: d31dms58

BACKGROUND: The complications and sequelae of coronavirus disease 2019 (COVID-19) and their effect on long-term health are unclear, and the trajectory of associated immune dysregulation poorly understood. METHODS: We conducted a prospective longitudinal multi-center cohort study at four public hospitals in Singapore. COVID-19 patients were monitored for a median of six months after recovery from acute infection. Clinical symptoms and radiologic data were collected, along with plasma samples for quantification of immune mediators. The relationship between clinical symptoms and immune cytokine profiles was investigated. RESULTS: 288 participants were recruited, and follow-up data were available for 183, 175, and 120 participants at days 30, 90 and 180 post-symptom onset respectively. Symptoms related to COVID-19 were present in 31 (16.9%), 13 (7.4%), and 14 (11.7%) at days 30, 90 and 180. In a multivariable model, age >65 years, non-Chinese ethnicity, and the severity of acute infection were associated with increased likelihood of persistent symptoms. Recovered COVID-19 patients had elevated levels of pro-inflammatory IL-17A, SCF, IL-12p70, IL-1βand pro-angiogenic MIP-1β, BDNF, VEGF at day 180 compared to healthy controls. Higher levels of MCP-1 and PDGF-BB were detected in patients with persistent symptoms, versus symptom-free patients. CONCLUSIONS: About 10% of recovered patients had persistent symptoms six months after initial infection. Immune cytokine signatures of the recovered patients reflected ongoing chronic inflammation and angiogenesis. COVID-19 patients should be monitored closely for emerging long-term health consequences.

M a n u s c r i p t

The collective understanding of coronavirus disease 2019 has evolved rapidly since its emergence, with recognition of the causative virus, evaluation of effective therapeutics, and development of multiple vaccines within the span of a year. However, there remain significant unanswered questions with regard to the long-term sequelae associated with COVID-19. Persistent symptoms post-COVID-19 recovery, termed "long COVID", have been reported, describing a clinical phenotype resembling myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), with prominent features of myalgia and fatigue [1, 2] . However, there are limited data as to the frequency of such symptoms or the pathophysiologic mechanisms driving them [3] . Studies have reported dysregulated cytokine release in acute COVID-19 patients associated with worse disease outcomes [4, 5] . However, the dynamics of cytokine response during recovery and its association with recovery trajectories and long-term outcomes have not been well studied.

Cohort studies tracking COVID-19 patients post-recovery described a high frequency (55% to 87.6%) of persistent symptoms (most commonly fatigue and dyspnea) for up to several months, with an associated decrease in quality-of-life [6] [7] [8] [9] . However, some of these are limited by their single-center study design, small sample sizes, and an absence of correlation with objective biomarkers of disease activity or immune dysregulation to explain persistent symptoms.

In this prospective multi-center cohort study, we aimed to assess the frequency of persistent symptoms up to six months across a spectrum of confirmed COVID-19 patients with varying initial disease severity. We also studied the longitudinal temporal dynamics of cytokine response, and determined the relationship of persistent symptoms with immune cytokine profiles during the recovery course.

A c c e p t e d M a n u s c r i p t

This was a multi-center study conducted in four public hospitals in Singapore that managed COVID- 19 inpatients. As part of enhanced surveillance in line with national public health policy, all patients with upper respiratory tract infection or pneumonia are tested for COVID-19 with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) polymerase chain reaction (PCR). Additionally, a large number of asymptomatic individuals were tested, namely close contacts of confirmed cases and individuals living in congregate settings (namely migrant worker dormitories where large outbreaks occurred). Hence, confirmed diagnoses included a large proportion of mild and asymptomatic cases. In the initial phase of the outbreak, all patients with confirmed COVID-19 infection were hospitalized for initial evaluation, regardless of illness severity.

Inclusion criterion was confirmed COVID-19 via SARS-CoV-2-specific PCR and admitted in the study period from January 30 th to August 14 th 2020. There were no pre-defined exclusion criteria. Patients were invited to participate; however not all patients could be approached due to resource limitations at the peak of the outbreak. Participants were offered outpatient follow-up postdischarge at 30, 90, 180, 270, and 360 days post-symptom onset (DPSO).

Clinical data were extracted from the electronic medical record using a standardized data collection form adapted from the International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC) case record form [10] . Disease severity was categorized based on worst clinical status during hospital admission: mild (no pneumonia on chest radiographs [CXR] throughout admission), moderate (pneumonia on CXR without hypoxia), and severe (pneumonia with hypoxia [oxygen saturation ≤94%] requiring supplemental oxygen). Severe was further sub-divided into non-critical A c c e p t e d M a n u s c r i p t (not requiring intensive care unit [ICU] admission) and critical (requiring ICU admission or mechanical ventilation) for the clinical analysis.

Patients were followed up post-discharge at multiple time points (approximately 30, 90, and 180-DPSO). A standardized symptom questionnaire was administered at each outpatient visit, in addition to an objective assessment and physical examination by a study physician.

Plasma samples were collected in cell preparation tubes during hospital admission on days 1, 3, 7, 14, 21, and 28 (if still admitted), and at each outpatient clinic visit on days 30, 90, and 180.

Plasma samples were extracted and treated with a solvent/detergent based on Triton X-100 (1%) for virus inactivation [11] . Immune mediator levels were measured using Cytokine/Chemokine/Growth Factor 45-Plex Human ProcartaPlex™ Panel 1 (ThermoFisher Scientific, Waltham, MA) (full details in Supplementary Methods). Cytokine levels were also measured in 24 healthy donor (10 males, 14 females; median age 55 years; details in Supplementary Table S1) plasma samples as baseline controls.

Unpaired t-test or Mann-Whitney U test was applied to ascertain significant differences in immune mediator levels between COVID-19 patients and healthy controls at different DPSO and between patients with and without persistent symptoms. A multiple linear regression analysis was conducted to examine the association between plasma cytokines and the presence of symptoms in COVID-19 patients after adjustment for age and disease severity. Two-way repeated measure ANOVA with Tukey post hoc correction for multiple testing was used to discern the differences between various disease severity groups and timepoints. Plots were generated using GraphPad Prism version 8 (GraphPad Software, San Diego, CA). ClustVis was used to compute hierarchical clustering and heat map on the immune mediators [12] . In the heat map presentation, the concentrations of immune Mann-Whitney U test was used to compare continuous variables and Fisher's exact test for categorical variables. Variables that were significantly different between participants with and without persistent symptoms in univariate analysis were selected to construct a multivariable logistic regression model to identify variables independently associated with risk of developing persistent symptoms. P-values <0.05 were considered statistically significant, and all tests were 2tailed. Analyses were performed using Stata Release 13 (StataCorp, College Station, TX).

Written informed consent was obtained from all study participants. The study protocol was 

288 participants were recruited into the study and consented for outpatient follow-up and serial blood sample collection (see Supplementary Figure S1 for study recruitment flowchart 

The number of patients with persistent symptoms at day 30, 90, and 180 were 31 (16.9%), 13 (7.4%), and 14 (11.7%) respectively. The detailed breakdown of individual symptoms is shown in Supplementary Table S2 . Symptoms were predominantly pulmonary, with the most common being cough and dyspnea. Participants with persistent symptoms at either day 90 or 180 were older, had a higher Charlson's comorbidity index, and were more likely to have required supplemental oxygen or ICU admission during their index hospitalization (Table 1) . Ethnicity was significantly different between patients with and without persistent symptoms, although we did not capture detailed ethnicity data for those outside the three major categories used in Singapore. In the multivariable model imputing age, sex, ethnicity, Charlson's comorbidity index, and disease severity; age group >65 years old, non-Chinese ethnicity, and critical illness severity (defined as ICU admission or requiring mechanical ventilation) during the index admission were independently associated with increased odds of persistent symptoms ( Table 2) .

Follow-up CXRs were reviewed for all patients with an initial abnormal CXR, and the latest abnormal CXR date was recorded in relation to the symptom onset date. Median time to resolution of CXR opacities was 14 days (IQR 9-32, range 1-195). However, as CXRs were not systematically repeated in a protocolized manner, there was a wide range of durations between follow-up CXRs. Hence, we did not further analyze this.

There was a prominent increase in levels of inflammation-associated markers interleukin (IL)-6, IL Table S6 ). Overall, persistent symptoms in recovered COVID-19 patients might be associated with elevated levels of MCP-1 in the early convalescent phase and PDGF-BB at 30-day assessment or later.

In this multi-center cohort study, COVID-19 was associated with a significant but overall low frequency of persistent symptoms after resolution of the acute illness: 7.4% and 11.7% at 90 and 180 days respectively. This is lower compared to other similar cohort studies in Italy, France, the United Kingdom, and China which reported persistent symptoms in 55% to 87.6% of patients [6] [7] [8] [9] .

Despite the proportion of severe initial infections being similar in our cohort compared with these cohorts (18% admitted to ICU compared to 12.6%, 20%, 32%, and 4% respectively) [6] [7] [8] [9] , we showed that cytokine expression for proinflammatory cytokines was only marginally different in follow-up samples for those with initial severe disease compared with asymptomatic and mildly infected For example, differences in demographics and ethnicity may explain this discordance in the frequency of persistent symptoms. Epidemiologic studies of ME/CFS demonstrated differences in incidence rates across ethnic groups [13] , which may be explained by genetic differences as specific Human Leukocyte Antigen (HLA) alleles were associated with ME/CFS [14] . Indeed, in our cohort, there were significant differences in the frequency of persistent symptoms across ethnic groups (with higher proportions in the "Others" category which included those of European descent), which merits further investigation. While Huang and colleagues found a high proportion (76%) of persistent symptoms in a Chinese cohort, they had a much higher proportion of patients with severe disease (75% requiring supplemental oxygen), which may explain the difference between our cohorts [9] . We found that COVID-19 patients had distinct systemic cytokine profiles at up to six months postsymptom onset compared with healthy controls, regardless of initial severity of illness or persistent symptoms. Levels of pro-inflammatory T-cell associated cytokines such as IL-17A, IL-12p70, IL-1β, and SCF were elevated and increased post-discharge. IL-12p70, SCF, and IL-17A have been found to be associated with chronic inflammatory diseases like ME/CFS and inflammatory spondyloarthropathy [15, 16] . Liu and colleagues found that convalescent individuals still experienced enhanced CD4 and CD8-T cell activation and proliferation, along with a contraction of

A c c e p t e d M a n u s c r i p t colleagues observed that persistent inflammation correlates with activation of cell metabolic pathways [18] . This sustained immune and metabolic dysregulation may be a driver of chronic inflammation in recovered COVID-19 patients.

Our longitudinal analyses of cytokine responses in recovered patients revealed subclinical changes potentially underpinning the development of post-COVID-19 cardiovascular complications even in those who did not have persistent symptoms. Regulators of endothelial activation such as VEGF, BDNF, and MIP-1 could promote atherosclerosis and potentially result in silent coronary artery disease [19] [20] [21] [22] . Convalescent patients were found to have pronounced endothelial activation hallmarks, abnormal cardiovascular imaging findings, and ongoing myocardial inflammation after COVID-19 recovery [23, 24] . Our findings of persistent elevation of pro-angiogenic factors warrants long-term monitoring and assessment of potential cardiovascular effects.

PDGF-BB, a potent chemotactic growth factor that stimulates the growth and migration of lung fibroblasts, has been implicated in the pathogenesis of pulmonary fibrosis [25] , while elevated levels of MCP-1 in patients with chronic obstructive pulmonary disease play a role in inducing emphysema [26] . Increased levels of PDGF-BB and MCP-1 in patients with persistent respiratory symptoms suggest a mechanism for chronic lung disease and therapeutic strategies targeting these immune mediators could be beneficial to ameliorate the progression of pulmonary symptoms in recovered COVID-19 patients [27, 28] .

There are several limitations to our study. Firstly, while we correlated the presence of persistent symptoms with cytokine features, we did not systematically evaluate end-organ involvement using functional assessments such as lung function tests, exercise tolerance scales, or detailed imaging.

Secondly, symptom questionnaires were qualitative and we did not utilize quantitative indices to measure impact on quality-of-life or functional status; there may thus be inter-subject variability and subjectivity. Thirdly, we did not have a control group to compare the frequency of persistent symptoms following other respiratory viruses in order to determine whether COVID-19 is associated A c c e p t e d M a n u s c r i p t with an increased risk of persistent symptoms. We also cannot be certain whether reported symptoms are due to COVID-19 or other conditions. Lastly, a significant proportion of patients were lost to follow-up, which may introduce an element of selection bias. However, it is likely that those who defaulted further follow-up were more likely to not have persistent symptoms, as those with persistent symptoms would be expected to have continued seeking medical care, and as such selection bias is more likely to have over-estimated the frequency of persistent symptoms.

Differences among study cohorts make comparison of persistent COVID-19 symptoms difficult, and a consensus case definition should be developed to standardize diagnosis and data collection to better understand this condition. The relatively non-specific and subjective nature of persistent symptoms makes the clinical picture harder to define. Establishing a causal link between COVID-19 and persistent symptoms remains challenging in the absence of a control group of non-COVID-19

patients. The presence of persistent symptoms post-hospitalization has been described in many conditions, including community-acquired pneumonia [29] , severe acute respiratory syndrome (SARS) [30, 31] , Middle East respiratory syndrome (MERS) [32] and a general "post-ICU syndrome" [33, 34] .

Nevertheless, the persistent symptoms of COVID-19 should not be overlooked, given the significant impact on quality-of-life and functional status, and a potentially huge impact on costs and resource utilization. It is clear that there are long-lasting immune changes triggered by COVID-19 infection, and while we could not establish a strong association between these immune signatures and persistent symptoms in our study, it is an intriguing signal that requires further study.

Further questions remain regarding persistent COVID-19. While we have demonstrated differences in the immune signatures of recovered COVID-19 patients, the mechanism behind this remains unclear. Prolonged viral shedding of SARS-CoV-2 nucleic acid has been observed from the respiratory tract, though multiple studies have shown that these are largely non-viable genetic material [4, 35] . SWXO and SWF have full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. M a n u s c r i p t M a n u s c r i p t M a n u s c r i p t A c c e p t e d M a n u s c r i p t Longitudinal plasma samples were collected across 4 timepoints up to 180 days post-symptom onset from 64 COVID-19 patients with different disease severity outcomes (mild, n=18; moderate, n=23; severe, n=23). Concentrations of 45 immune mediators were quantified using a 45-plex microbead-based immunoassay. The levels of immune mediators that persist high in COVID-19 patients at 180 days post-symptom onset at various timepoints were shown as mean ± SEM. Two-way repeated measure ANOVA with Tukey post hoc correction for multiple testing was used to discern the differences between various disease severity groups and timepoints (*p < 0.05; **p < 0.01; ***p < 0.0001). Mean levels of immune mediators for healthy controls are indicated by the black dotted line. Patient samples with concentration out of measurement range are presented as the value of logarithm transformation of Limit of Quantification.

A c c e p t e d M a n u s c r i p t 

Covid-19: What do we know about "long covid

The lasting misery of coronavirus long-haulers

Long-term consequences of COVID-19: research needs

Viral dynamics and immune correlates of COVID-19 disease severity

Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes

Persistent Symptoms in Patients After Acute COVID-19

Post-discharge persistent symptoms and healthrelated quality of life after hospitalization for COVID-19

Postdischarge symptoms and rehabilitation needs in survivors of COVID-19 infection: A cross-sectional evaluation

6-month consequences of COVID-19 in patients discharged from hospital: a cohort study

COVID-19 CRF -ISARIC. Available at

Evaluation of inactivation methods for severe acute respiratory syndrome coronavirus in noncellular blood products

ClustVis: a web tool for visualizing clustering of multivariate data using Principal Component Analysis and heatmap

A systematic review of chronic fatigue, its syndromes and ethnicity: prevalence, severity, co-morbidity and coping

Human Leukocyte Antigen alleles associated with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)

Cytokine signature associated with disease severity in chronic fatigue syndrome patients

IL-17 in the immunopathogenesis of spondyloarthritis

The analysis of the long-term impact of SARS-CoV-2 on the cellular immune system in individuals recovering from COVID-19 reveals a profound NKT cell impairment

Early immune pathology and persistent dysregulation characterise severe

Vascular Endothelial Growth Factor (VEGF) and Its Receptor (VEGFR) Signaling in Angiogenesis: A Crucial Target for Anti-and Pro-Angiogenic Therapies

Brain-derived neurotrophic factor: a newly described mediator of angiogenesis

Inhibition of macrophage inflammatory protein-1beta improves endothelial progenitor cell function and ischemia-induced angiogenesis in diabetes

Angiogenesis in the atherosclerotic plaque

Convalescent COVID-19 patients are susceptible to endothelial dysfunction due to persistent immune activation

Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease 2019 (COVID-19)

Regulation of PDGF and its receptors in fibrotic diseases

Blood MCP-1 levels are increased in chronic obstructive pulmonary disease patients with prevalent emphysema

Role of Platelet-Derived Growth Factor (PDGF) in Asthma as an Immunoregulatory Factor Mediating Airway Remodeling and Possible Pharmacological Target

Pulmonary Fibrosis in COVID-19 Survivors: Predictive Factors and Risk Reduction Strategies

Measuring symptomatic and functional recovery in patients with community-acquired pneumonia

Mental morbidities and chronic fatigue in severe acute respiratory syndrome survivors: long-term follow-up

The long-term impact of severe acute respiratory syndrome on pulmonary function, exercise capacity and health status

Long-term clinical outcomes in survivors of severe acute respiratory syndrome and Middle East respiratory syndrome coronavirus outbreaks after hospitalisation or ICU admission: A systematic review and meta-analysis

Long-term outcome after the acute respiratory distress syndrome: different from general critical illness?

Post-ICU syndrome: Rescuing the undiagnosed

Predicting infectious SARS-CoV-2 from diagnostic samples

Persistence of viral RNA, pneumocyte syncytia and thrombosis are hallmarks of advanced COVID-19 pathology

A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t